Pregnanolone derivatives substituted in 3alpha-position with the cationic group, usage and pharmaceutical preparation involving them
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00500216" target="_blank" >RIV/61388963:_____/18:00500216 - isvavai.cz</a>
Alternative codes found
RIV/67985823:_____/18:00500216
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180418&DB=&locale=en_EP&CC=EP&NR=2675821B1&KC=B1&ND=4#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180418&DB=&locale=en_EP&CC=EP&NR=2675821B1&KC=B1&ND=4#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Pregnanolone derivatives substituted in 3alpha-position with the cationic group, usage and pharmaceutical preparation involving them
Original language description
The presented invention applies to pregnanolone derivatives, substituted in 3 alpha-position with the cationic group, of general formula I, the method of the production of these compounds and their utilization for treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post traumatic stress dissorder, and other diseases related to stress, anxiety, schizophrenia, and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy, and gliomas. The object of invention is also the use of compounds of general formula I for production of veterinary and human pharmaceutical preparation for treatment of above mentioned diseases and for production of pharmaceutical preparations containing these compounds.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP2675821
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Apr 18, 2018
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence